Intrexon Corporation June 15th Short Interest Update

Intrexon Corporation (NYSE:XON) reported a rise of 5.6% or 891,980 shares in its short interest. The short figure came in at 30.8% of the total floats. The average daily volume of 1,491,400 shares suggests that the days to cover 16,818,613 short positions, as on June 15,2016, will be 11. On May 31,2016, the short interest was 15,926,633 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Intrexon Corporation (NYSE:XON): The stock opened at $23.99 on Friday but the bulls could not build on the opening and the stock topped out at $25.48 for the day. The stock traded down to $23.95 during the day, due to lack of any buying support eventually closed down at $24.00 with a loss of -4.76% for the day. The stock had closed at $25.20 on the previous day. The total traded volume was 2,440,533 shares.

The company shares have dropped -49.16% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $69.45 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $26.96 and the 200 Day Moving Average price is recorded at $30.47.

Stocks of Intrexon Corporation (NYSE:XON) rallied by 0.21% during the past week but lost 20.05% on a 4-week basis. The company has outperformed the S&P 500 by 1.87% in the past week but underperformed the index by 17.63% in the last 4 weeks.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.